NSE: CIPLA | BSE: 500087

Mid-range Performer

Download real time

1488.00 -11.40 (-0.76%)

1.8M NSE+BSE Volume

NSE 29 Sep, 2025 3:31 PM (IST)

120,195.5

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Cipla Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for CIPLA, BSE:500087 Cipla Ltd.

Search Inside the pdf :

Cipla Ltd.

08 Sep 2025

1488.00

-0.76%

Growth outlook intact despite near-term headwinds

Hold: Cipla Ltd.

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by +0.9%/-5.2%, as we factor in lower revenue on account of ramp down of Revlimid portfolio and ongoing price erosion in the US market, higher depreciation and amortization expense, offset by higher other income.

Cipla Ltd. is trading below all available SMAs

Cipla Ltd.

02 Sep 2025

1488.00

-0.76%

India, RoW biz to stay steady, US drug pipeline - the next trigger

Buy: Cipla Ltd.

Target

Sharekhan

Cipla has robust domestic and global product pipelines. US product pipeline to be healthy and will be key to driving growth from H2FY26E and contribute significantly from FY27E onwards.

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

Cipla Ltd.

28 Jul 2025, 12:00AM

1488.00

-0.76%

Result Update:Cipla

Buy: Cipla Ltd.

Axis Direct

We remain positive on the stock with a BUY rating and arrive at a target price of Rs 1,700 per share.

Cipla Ltd. has an average target of 1702.60 from 10 brokers.

Cipla Ltd.

27 Jul 2025

1488.00

-0.76%

Cipla (CIPLA IN) Q1FY26 Result Update Strong US...

Buy: Cipla Ltd.

Prabhudas Lilladhar

CIPLA's Q1FY26 EBITDA (Rs17.8bn; 25.6% OPM) was 6% ahead of our estimates. Cipla managed to deliver strong margins during the quarter. During the quarter company witnessed price erosion for its generic products which was offset by new launches such as gAbraxane. Mgmt guided strong US revenues of $1bn for FY27 despite gRevlimid erosion. We expect Cipla to maintain its existing US sales run-rate. This will be aided by several high value niche launches in the US like gAbraxane, Nilotininb, gAdvair. Further, Cipla's...

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

Cipla Ltd.

26 Jul 2025

1488.00

-0.76%

US business on a strong footing

Buy: Cipla Ltd.

Target

ICICI Securities Limited

Cipla reported an in-line Q1FY26 result led by growth across the US and South Africa. Despite price erosion in gRevlimid, it posted a 156bps YoY (+133bps QoQ) surge in gross margin to 68.8%.

Cipla Ltd. has an average target of 1702.60 from 10 brokers.

Cipla Ltd.

14 May 2025

1488.00

-0.76%

Cipla (CIPLA IN) Q4FY25 Result Update In-line EBITDA;...

Buy: Cipla Ltd.

Prabhudas Lilladhar

CIPLA's Q4FY25 EBITDA (Rs15.4bn; 22.8% OPM) was in line with our estimates. While Q4 is seasonally weak quarter; margins at 23% were above our estimate. Despite delay in new launches and supply issues of gLanreotide; Cipla managed to deliver strong profitability/margins in H2FY25. We expect Cipla to maintain its existing US sales run-rate. This will be aided by several high value niche launches in the US like gAbraxane, Nilotininb, gAdvair. Further, Cipla's...

Cipla Ltd. has an average target of 1702.60 from 10 brokers.

Cipla Ltd.

11 Apr 2025

1488.00

-0.76%

Cipla (CIPLA IN) Event Update Gets approval for...

Buy: Cipla Ltd.

Prabhudas Lilladhar

Cipla has secured its much awaited USFDA approval of gAbraxane following Change in Estimates | Target | Reco the Goa facility clearance in November 2024, milestone that reinforces our positive stance on the company. Our FY26E and FY27E EPS factors in...

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

Cipla Ltd.

29 Jan 2025, 12:00AM

1488.00

-0.76%

CIPLA LTD.

Buy: Cipla Ltd.

Prabhudas Lilladhar

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

Cipla Ltd.

29 Jan 2025, 12:00AM

1488.00

-0.76%

Result Update:Cipla

Buy: Cipla Ltd.

Axis Direct

We maintain our BUY recommendation with a target price of Rs 1,700/share.

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

Cipla Ltd.

28 Jan 2025, 12:00AM

1488.00

-0.76%

3Q results beat estimates; yet to scale up Lanreotide supply

Neutral: Cipla Ltd.

Recommendation Target

Motilal Oswal

CIPLA delivered better-than-expected 3QFY25 earnings. While revenue was in line, EBITDA/adj. PAT beat our estimates, aided by a better product mix and lower R&D spending.

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

Is Cipla Ltd. worth buying?

625 Votes:

Buy 75.84%

Sell 13.92%

Hold 10.24%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf